Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)

Inclusion Criteria Patients must have the following: Stage III or IV HIV infection. Provide informed consent. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Kaposi's sarcoma lesions in the proposed treatment sites. Liable to require radiation or chemotherapy during the course of the study. Not likely to survive the length of the study. Obvious ultra-violet-irradiated skin damage in the treatment areas and anyone with recent UV exposure or likely to have such exposure (e.g.: holiday tans obtained in Hawaii, members of UV box tanning salons, etc.) Allergy to lidocaine. Concurrent Medication: Excluded: Other Immunomodulators. Concurrent Treatment: Excluded: Radiation. Patients with the following are excluded: Kaposi's sarcoma lesions in the proposed treatment sites. Liable to require radiation or chemotherapy during the course of the study. Not likely to survive the length of the study. Obvious ultra-violet-irradiated skin damage in the treatment areas. Allergy to lidocaine. Prior Medication: Excluded: Prior DNCB therapy.